Related Experiment Video
Updated: Aug 5, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
Ventricular Assist Device Use in Single Ventricle Heart Disease: Current Outcomes and Considerations
T Miller Sisson1, Erin V Shea2
1Pediatric Cardiology, Duke Children's Pediatric and Congenital Heart Center, Duke University Medical Center, Durham, NC, USA. miller.sisson@duke.edu.
Purpose Of Review:
Heart failure in patients with congenital heart disease and particularly single ventricle physiology at all stages of palliation presents significant management challenges. Ventricular assist device (VAD) use in this population is increasing. This review summarizes the recent outcomes, physiologic considerations, and challenges of VAD therapy at each stage of single ventricle palliation.
Recent Findings:
Survival after VAD implantation has been worse for patients with single ventricle physiology compared with biventricular physiology, though recent data suggest this disparity is narrowing. A variety of continuous and pulsatile flow devices are available for use, though many are not approved by the Food and Drug Administration for use in the pediatric population. Adverse effects are common with VADs at each stage of single ventricle palliation, regardless of device choice. VAD therapy in patients with single ventricle heart disease requires an understanding of the complex cardiac physiology and device mechanics in order to optimize outcomes.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
